mTOR抑制剂在癌症治疗中的应用PPT.ppt

mTOR Inhibitors (mTOR抑制剂)in Cancer Therapy;;mTOR is an intracellular serine-threonine kinase (丝氨酸-苏氨酸激酶) mTOR is downstream of growth factor/nutrient and PI3k/AKT signalling pathway (信号通路中的下游分子) mTOR is a central regulator of protein synthesis Activated by mutations in cancer;mTOR Pathway Activation;;Clinical Development of mTOR Inhibitors(Derivates of rapamycin );mTOR inhibition  (Similar mechanism of action);mTOR Inhibitors: Derivates of Rapamycin;mRCC;Standards for RCC Therapy by Phase III Trial after ASCO 2007;RAD001 (everolimus); Everolimus (RAD001, Afinitor) in RCCRationale ;Better Inhibition of p70S6 Kinase With Daily Schedule;Phase II Trial of RAD001 in mRCC (Amato);Objectives (end Point) Primary: PFS Secondary: Safety; Response; Patients reported outcome; OS;RECORD-1 Phase III study design(随机III期试验:比较RAD001与安慰剂);Progression-Free Survival by Treatment Central Radiology Review;Progression-Free Survival by Treatment Investigator Assessment;Subgroup Analysis of Progression-Free Survival Central Radiology Review;Treatment-Related Adverse Events*;Conclusions;Standards for RCC Therapy by Phase III Trial after ASCO 2008;Everolimus : Development Overview;Thank You !